KYMR · Company research
Kymera Therapeutics, Inc. Common Stock (KYMR): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
15records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth? | Kymera Therapeutics is developing KT-621, an oral STAT6 degrader in phase IIb trials for atopic dermatitis and eosinophilic asthma. The company completed enrollment in the BROADEN2 study ahead of schedule with top-line data expected by end of 2026. Future growth depends on trial outcomes, regulatory approval, and successful commercialization. The company faces competition from Arvinas and Nurix in the protein degradation therapy space. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.333 | 1 |
| Understanding Momentum Shifts in (KYMR) - Stock Traders Daily | Understanding Momentum Shifts in (KYMR) Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 12, 2026 | neutral | 0 | 0.6 |
| Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock Has Average Target Price of $134.68 - MarketBeat | Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock Has Average Target Price of $134.68 MarketBeat | View source ↗ | MarketBeat | Oct 10, 2026 | neutral | 0 | 0.6 |
| Kymera: Over-Hyped, Or Developing Next Dupixent? We'll Find Out Very Soon - Seeking Alpha | Kymera: Over-Hyped, Or Developing Next Dupixent? We'll Find Out Very Soon Seeking Alpha | View source ↗ | Seeking Alpha | Oct 9, 2026 | neutral | 0 | 0.6 |
| Kymera Therapeutics (NASDAQ:KYMR) Stock Falls 5% - Should You Sell? - MarketBeat | Kymera Therapeutics (NASDAQ:KYMR) Stock Falls 5% - Should You Sell? MarketBeat | View source ↗ | MarketBeat | Oct 6, 2026 | neutral | 0 | 0.6 |
| After exercising options at $2.08 a share, Kymera Therapeutics (KYMR) CEO sells 30,000 shares. - Stock Titan | After exercising options at $2.08 a share, Kymera Therapeutics (KYMR) CEO sells 30,000 shares. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| A 30,000-share sale is planned by Kymera Therapeutics (KYMR) officer and director Nello Mainolfi. - Stock Titan | A 30,000-share sale is planned by Kymera Therapeutics (KYMR) officer and director Nello Mainolfi. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| Kymera Therapeutics (NasdaqGM:KYMR) Stock Forecast & Analyst Predictions - Simply Wall Street | Kymera Therapeutics (NasdaqGM:KYMR) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 1, 2026 | neutral | 0 | 0.6 |
| A 9-Day Winning Streak Has Kymera Therapeutics Stock Up 17% - Trefis | A 9-Day Winning Streak Has Kymera Therapeutics Stock Up 17% Trefis | View source ↗ | Trefis | Aug 17, 2026 | neutral | 0 | 0.6 |
| Kymera Therapeutics (KYMR) Stock Gets Fair Value Bump After KT 621 Timeline Shift - Yahoo Finance | Kymera Therapeutics (KYMR) Stock Gets Fair Value Bump After KT 621 Timeline Shift Yahoo Finance | View source ↗ | Yahoo Finance | Jul 2, 2026 | neutral | 0 | 0.6 |
| KYMR Forecast — Price Target — Prediction for 2027 - TradingView | KYMR Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline - Stocktwits | KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline Stocktwits | View source ↗ | Stocktwits | Jun 25, 2026 | neutral | 0 | 0.6 |
| Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock? - Yahoo Finance | Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Jun 23, 2026 | neutral | 0 | 0.6 |
| Insider Sale: Director at $KYMR Sells 9,584 Shares | KYMR Stock News - Quiver Quantitative | Insider Sale: Director at $KYMR Sells 9,584 Shares | KYMR Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Jun 23, 2026 | neutral | 0 | 0.6 |
| KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug - Yahoo Finance | KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug Yahoo Finance | View source ↗ | Yahoo Finance | Apr 14, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.